Kevin Robb, PhD

PhD in Biomedical Engineering studying cell therapy for osteoarthritis |
University of Toronto & University Health Network | He/Him 🏳️‍🌈

[Kevin Robb, PhD @KP_Robb]

🚨NEW PAPER ALERT🚨
Wondering how to evaluate the immunomodulatory or angiogenic fitness of your mesenchymal stromal cells? This may help...

I'm so excited to share my first original research article from my PhD work published TODAY in @FrontImmunol 🎉👇 https://t.co/cRgBhsU3SK

[Stem Cell Network @StemCellNetwork]

Join us on November 20 for Careers Beyond Academia, a virtual series by SCN and @MbD_UofT!

@KP_Robb and @spicedanielle will dive into industry roles, big vs. small companies, and translating research to the real world. 🌍

Learn more and register. ➡️ https://t.co/yNGT4cQhQQ

[Signals @Signalsblogs]

Blogger @KP_Robb shares lessons learned from market-approved #MSC products at a talk @ISCTglobal with @stempeutic and @TakedaPharma https://t.co/poQoDsxRDE #clinicaltrials #regulatoryapprovals

[Schroeder Arthritis Institute @SchroederInst]

Meet Atoosa Ziyaeyan, PhD Student within the Division of #Orthopedics at @SchroederInst , supervised by Dr. Sowmya Viswanathan. She is working on finding the link between gut microbiome changes and knee joint #osteoarthritis.
#TraineeTuesday

[Priye Iworima, MSc. PhD.🇳🇬 (Black lives matter) @IworimaPriye]

‼️🚨 New publication alert 🚨‼️

Please #repost

Check out our paper making stem cell-derived insulin-producing cells using a monolayer-suspension hybrid bioprocess workflow in cellSTACKs and PBS Minis.

https://t.co/YDDLsaGx8d

[Kevin Robb, PhD @KP_Robb]

Nice to see a couple of my blogs made the Signals Top 10 list of 2023! Thank you @Signalsblogs & @msstaceyerin !

[Signals @Signalsblogs]

Here is the must-read blog from 2023 on Signals, compiled by @msstaceyerin https://t.co/sn323PMcmA @LaineBComms @KP_Robb @Sara_M_Nolte @Makuopeace @CalStrode

[Signals @Signalsblogs]

Signals editor @msstaceyerin sums up a year of blogging and teases 2024. Thank you to our bloggers and readers! Wishing you all the best in the new year. https://t.co/cK3y6m6u4e @acapellascience

[Tyler J Wenzel @TylerJWenzel]

It was ~8 years ago that I told an undergrad that 'Gene Therapies' are sci-fi. We had the tools, but no where near therapies.

Now, it seems like we are about to announce that we've cured every monogenic disease.
Read the @Signalsblogs (@CCRM_ca) 👉https://t.co/YP4e8DFOSy 🧵(1/4)

[Kevin Robb, PhD @KP_Robb]

@TylerJWenzel @Signalsblogs @CCRM_ca Great post, Tyler! Exciting times indeed! 🧑‍🔬

[Kevin Robb, PhD @KP_Robb]

@IworimaPriye

[Priye Iworima, MSc. PhD.🇳🇬 (Black lives matter) @IworimaPriye]

🚨NEW PAPER ALERT🚨

Check out our paper on hESC aggregation across multiple cell culture platforms, and their capacity to differentiate into hormone-producing cell clusters. 

Shoutout to the fantastic team of co-authors🪅🎉

https://t.co/djY3w0eytG

#bioprocess #diabetes

[Signals @Signalsblogs]

Allo or auto? New blogger @TylerJWenzel examines allogeneic vs autologous #celltherapies and shares methods from the research of Dr. Akitsu Hotta (@KyotoU_News), presented at #TMM2023, to reduce the risks of allogeneic cell therapies. https://t.co/zM7cMdlVMN

[Signals @Signalsblogs]

New blogger Rebecca Ihilchik writes about the #HenriettaLacks lawsuit and examining scientific history from today's viewpoint. She recommends steps we can all take for incorporating #EDI to action change https://t.co/ybouMdhUP1

[Kevin Robb, PhD @KP_Robb]

@Signalsblogs @StemCellClubCA @warren_fingrut Great read!

[Kevin Robb, PhD @KP_Robb]

My latest blog post covers the bench-to-bedside story of BlueRock's investigational cell therapy for Parkinson's disease. Link below! 👇
https://t.co/rXhYei5as6…

[Signals @Signalsblogs]

Another talk at #TMM2023 was by Dr. Stefan Irion of @BlueRockTx on their #stemcell therapy for #Parkinsons. Read blogger @KP_Robb's post. Spoiler: BRTx has announced plans to begin enrolling patients for a Phase II #clinicaltrial in 2024 https://t.co/f8DIz6KA7d

[Kevin Robb, PhD @KP_Robb]

@MLithopoulos Thanks Marissa!!

[Kevin Robb, PhD @KP_Robb]

Spooky Halloween season is upon us! And with that comes a story on the PhD Afterlife 🪦🧟‍♂️
Here I've gathered perspectives from PhD holders on the utility of a postdoc as a next step in academic or industry career paths. Article link below! 🎃
https://t.co/gurgt6jLIv…

[Signals @Signalsblogs]

As hundreds of Cdn trainees gather in Toronto for @StemCellNetwork's #TMM2023, former #TCC vice chair @KP_Robb explores the value of a postdoc after a PhD https://t.co/X9LURW7qji with @TheJenMoody @nika_shakiba #JanetRothberg #ChristineGenge

[Tyler J Wenzel @TylerJWenzel]

And that’s a wrap on ELSI! Look at all those smiling faces!

Big thank you again to Caroline (@UCalgary), Chris (@FChrisBennett) and Bernard (@LabThebaud) for coming out to Toronto to speak about conducting ethical science at the bench, in the hospital, and in our communities.

[Signals @Signalsblogs]

With recent changes in the #SocialMedia landscape, where do scientists and engineers meet online for networking and #ProfessionalDevelopment? Comms expert @LaineBComms provides a helpful overview, with tips. https://t.co/1WCujVv18e #scicomm #STEM

[Kevin Robb, PhD @KP_Robb]

2) If you're interested in this emerging cell therapy but unfamiliar with the specifics of the MSC field, you can also check out my previous @Signalsblogs post covering the same topic here! 👇
https://t.co/EJzMxcqscZ

[Kevin Robb, PhD @KP_Robb]

A tale of two pubs:
1) Our paper discussing the path forward to commercially-approved mesenchymal stromal cell (MSC) therapies is now out! The article recaps a discussion @ISCTglobal covering patient stratification, CQAs & next-gen products. Link 👇
https://t.co/tEdB2s0aeT